MK-4166
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-4166, covering 2020-07-31 to 2020-07-31. Get the full timeline:
Most recent: Clinical Trial Update: Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) [Phase 1]